Cytotoxic T lymphocytes (CTLs
Introduction
Immunotherapy has long been considered the fourth type CTLs are not simply expanded in vitro or in vivo . This is mainly because of difficulties in getting sufficient numbers of antigen-specific CTLs both in vivo and in vitro, which is attributable to the short life span of activated CTLs. In this article, we will introduce a novel approach able to overcome the above-mentioned problems by using induced pluripotent stem cell (iPSC) technology.
Immune checkpoint blockade is effective in cancer immunotherapy
CTLA-4 and PD-1 are inhibitory receptors expressed on activated T cells and important for the tuning of an immune reaction. By blocking these receptors with specific monoclonal antibodies (mAb), it is possible to augment an immune response. Indeed, anti-PD-1 mAb and anti-CTLA-4 mAb alone or in combination have been shown to be effective for some types of cancers including melanoma, lung cancer, and kidney cancer, even at the advanced stage [1] [2] [3] , having been already approved to use in certain types of cancers. These mAbs are thought to indirectly activate latent CTLs reactive to cancer cells present in patients.
Immune checkpoint blockade represents an epoch-making breakthrough in cancer therapy, since the approach is straightforward and has a broad applicability in a variety of cancer types. Nevertheless, some problems remain in that i) an autoimmune reaction takes place at a certain frequency, as this strategy activates the immune system in a non-antigen-specific manner, and ii) in most cases, the effect is limited to -20% of patients. For example, MART1-specific TCR gene has been used in a clinical trial against melanoma, and 10-30% of patients showed tumor regression 6, 7) . In another trial, T cells transduced with NY-ESO1-specific TCR have been shown to be effective in 60% of synovial cell sarcoma patients and 40% of melanoma patients 8) .
Adoptive transfer of T cells

A novel method for the cloning of T cells
Hereafter, we introduce our novel strategy, which is currently under development.
Methods to activate the immune system in a nonantigen-specific manner using immune checkpoint-blocking 
Production of iPSCs from tumor antigenspecific CTLs
Along with this idea, we have recently succeeded in establishing iPSCs from melanoma antigen MART1-specific CTLs originally derived from a melanoma patient, and in regenerating MART1-specific CTLs from these iPSCs 9) .
As a cell source we used JKF6 cells 10) , long-term cultured MART1-specific TILs that were originally derived from a melanoma patient ( Fig. 2A) . Although it has been previously shown that iPSCs can be produced from human peripheral T cells by using Yamanaka factors 11, 12) , we also used SV40 large T antigen 13) to increase reprogramming efficiency. For transduction, we used the Sendai virus system 14) . We thus succeeded in making iPSCs from MART1-specific CTLs (MART1-T-iPSCs) ( Fig. 2A,B) .
Regeneration of tumor antigen-specific CTLs from iPSCs
We then induced differentiation of T cells from MART1- 
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specific for the MART-1 antigen (Fig. 2E, right panel) .
To examine whether these CD8 + T cells can be activated in an antigen-specific manner, regenerated CD8 + T cells were co-cultured with target cells (human EBV-lympho-blastoid cell line) with or without MART-1 peptide. CD8 + T cells produced a substantial amount of IFNγ only in the presence of specific peptide (Fig. 2F) . Collectively, this T-iPSC approach appears to be effective in regenerating functional antigen-specific CTLs.
Application of this method to the allogeneic transplantation setting
The above method, which is based on the autologous transplantation setting, is bound to face some problems.
Not only will production of iPSCs for individual patients be costly, it will also be difficult to ensure TCR affinity and iPSC quality, and it will need a substantial amount of time (more than 6 months) to prepare regenerated CTLs.
We propose that an allogeneic transplantation strategy will solve these problems. In order to achieve such a strategy, it will be required to establish a "T-iPSC bank". In this scheme, T-iPSCs are produced from tumor antigen-specific CTLs collected from healthy donors (Fig. 3) . Regenerated CTLs will be tested with regard to TCR affinity, and if they are sufficient in quality, such T-iPSCs will be stored as frozen stocks in the bank. Regenerated CTLs themselves will also be frozen and pooled, such that they will be immediately 
Target antigens and cancer types
Apart from the example of regenerated CTLs specific for the melanoma antigen MART-1 we have shown here, what other candidate antigens and cancer types would potentially benefit from this approach? In general, cancers that are responsive to immune blockade reagents will be good targets. In this respect, lung cancers and kidney cancers, against which anti-PD-1 mAb was reportedly effective, have been listed as candidates 1) .
Regarding candidate tumor antigens, TCR-gene therapy trials against several tumor antigens have been already conducted, and some tumor antigens have been reported to be effective and also safe. Those antigens will be good candidates, and in this regard, WT1 (Wilm's tumor 1), NY-ESO-1, or LMP-2 might be suitable targets 16) .
It is also possible to target "mutated epitopes". Since cancer is usually monoclonal, mutations present in a Fig. 3 Application of the method to the allogeneic transplantation setting T-iPSCs are produced from tumor antigen-specific CTLs collected from healthy HLA haplotype homozygous donors. Regenerated CTLs will be tested with regard to TCR affinity, and if they are sufficient in quality, T-iPSCs will be stored as frozen stocks in the T-iPSC bank.
Frozen and pooled regenerated CTLs will then be available for immediate use in HLA-matched patients bearing cancer expressing the same tumor antigen.
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cancer-initiating cell that bring about alterations of amino acids in proteins are inherited in all progeny cells. Indeed, many types of cancer bear hundreds of such genomic mutations 17) . A recent study showed that cancers against which anti-CTLA-4 mAb had been effective were found to bear more mutations 18) , suggesting that at least some of the latent CTLs in cancer patients are targeting mutated epitopes.
Possible side effects
We have mentioned earlier that an autoimmune reaction is inevitable when using a non-antigen-specific strategy. In principle, antigen-specific strategies are able to avoid this type of side effect. However, some risks remain even in the case of antigen-specific strategies. Most tumor antigens are also expressed in normal tissues, although expression levels are usually low. For example, MART-1 is expressed in normal melanocytes, and TCR-gene therapy using MART1-specific TCR often results in vitiligo or vision disorder 7) .
In the case of gene therapy using T cells expressing an affinity-enhanced TCR against MAGE-A3, in which amino acids were altered by genetic engineering, the transferred cells led to two patients' deaths, caused by an unexpected TCR cross-reactivity of TCR 19) . Generation of a TCR with such unexpected specificity is attributed to artificial genetic engineering. On the other hand, in case of allogeneic transplantation, it is also possible that transferred T cells just happen to have specificity against allo-HLA or minor antigens. Therefore, the possibility of such risks should be carefully considered.
As to the reproducibility of antigen specificity, some risk 
Cancer as a target in regenerative medicine
In this article, we have introduced a strategy to regenerate CTLs using iPSC technology as a novel method in cancer immunotherapy. This strategy can also be categorized as one of the therapeutic approaches in regenerative medicine.
Application of iPSC technology has been primarily directed to cases in which compensation of lost organs is required, while it could also be used for drug screening or for drug toxicity testing. However, to date the number of target patients seems not so large. Our approach could make it possible for cancer patients to become targets of regenerative medicine. Just as we have exemplified here the case of malignant melanoma, a large number of peptide antigens recognized by CTLs has been identified comprising various types of solid tumors, including gastric cancer, colon cancer, lung cancer and breast cancer, to name a few 16) . This means that the T-iPSC strategy has the potential to target a broad range of cancer cases.
Perspective: toward clinical application
At present, we are endeavouring to establish T-iPSCs from CTLs specific for a number of cancer antigens from healthy donors. We have succeeded in establishing T-iPSCs from CTLs specific for tumor antigen WT1, which is known to be expressed in various types of cancer cells. We have optimized in vitro culture conditions and succeeded in regenerating CTLs expressing CD8 alphabeta heterodimers. These regenerated CTLs exhibited very high antigen-specific killing activity comparable to that of original CTLs. Regenerated CTLs were able to kill some leukemia cell lines which express endogenous WT1 protein.
The cells can be expanded more than ten thousand times by repeated TCR stimulation without reducing their killing activity during an additional several weeks.
Based on these results, we are planning to apply this method to leukemia patients. Aged acute myeloid leukemia patients to whom stem cell transplantation cannot be applied would be good candidates for this new strategy. We will collect WT1-specific CTLs from patients and generate WT1-T-iPS cells. It is also possible to prepare WT1-T-iPS cells from healthy volunteers to be used in the allogeneic setting. Which approach should be taken first will depend on regulatory issues.
